Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation

Experimental Hematology

Volumn 34, Issue 9, 2006, Pages 1270-1276

  Saito, Toshiki I ^a   Rubio, Marie T ^a   Sykes, Megan ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHIMERA; CONTROLLED STUDY; DONOR; EXPERIMENTAL MOUSE; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HOST; INTERMETHOD COMPARISON; LEUKOCYTE TRANSFUSION; LYMPHOCYTE TRANSFUSION; MOUSE; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL; TUMOR CELL; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; CLINICAL TRIAL; COMPARATIVE STUDY; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; METHODOLOGY; PATHOLOGY; SPECIES DIFFERENCE;

MURINAE;

ANIMALS; CLINICAL TRIALS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LYMPHOCYTE TRANSFUSION; MICE; MICE, INBRED BALB C; RISK FACTORS; SPECIES SPECIFICITY; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 33747890690     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.04.022     Document Type: Article

References (29)

1. Wysocki C.A., Panoskaltsis-Mortari A., Blazar B.R., and Serody J.S. Leukocyte migration and graft-versus-host disease. Blood 105 (2005) 4191-4199
2. Weissinger F., Sandmaier B.M., Maloney D.G., Bensinger W.I., Gooley T., and Storb R. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 98 (2001) 3584-3588
3. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
4. Sykes M., Preffer F., McAfee S., et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after nonmyeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 353 (1999) 1755-1759
5. Dey B.R., McAfee S., Colby C., et al. Anti-tumour response despite loss of donor chimaerism in patients treated with nonmyeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 128 (2005) 351-359
6. O'Donnell P.V., Luznik L., Jones R.J., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 8 (2002) 377-386
7. Rubio M.T., Kim Y.M., Sachs T., Mapara M., Zhao G., and Sykes M. Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma. Blood 102 (2003) 2300-2307
8. Kim K.J., Kanellopoulos-Langevin C., Merwin R.M., Sachs D.H., and Asofsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 122 (1979) 549-554
9. Pelot M.R., Pearson D.A., Swenson K., et al. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 5 (1999) 133-143
10. Kavanaugh D.Y., and Carbone D.P. Immunologic dysfunction in cancer. Hematol Oncol Clin North Am 10 (1996) 927-951
11. Wekerle T., Sayegh M.H., Hill J., et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 187 (1998) 2037-2044
12. Ballen K.K., Becker P.S., Emmons R.V., et al. Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood 100 (2002) 442-450
13. Porter D.L., Roth M.S., McGarigle C., Ferrara J.L., and Antin J.H. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330 (1994) 100-106
14. Chakraverty R., Côte D., Buchli J., et al. An inflammatory checkpoint regulates recruitment of graft-versus-host-reactive T cells to peripheral tissues. J Euro Med (2006) In Press
15. Kolb H.J., Schmid C., Barrett A.J., and Schendel D.J. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103 (2004) 767-776
16. Mapara M.Y., and Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22 (2004) 1136-1151
17. Adler A., Stein J.A., and Ben-Efraim S. Immunocompetence, immunosuppression, and human breast cancer. II. Further evidence of initial immune impairment by integrated assessment effect of nodal involvement (N) and of primary tumor size (T). Cancer 45 (1980) 2061-2073
18. Rubio M.T., Saito T.I., Kattleman K., Zhao G., Buchli J., and Sykes M. Mechanisms of the anti-tumor responses and host-versus graft reactions induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: a critical role for recipient CD4+ T cells and recipient leukocyte infusion-derived interferon-gamma-producing CD8+ T cells. J Immunol 175 (2005) 665-676
19. Larsen C.P., Elwood E.T., Alexander D.Z., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381 (1996) 434-438
20. Durie F.H., Fava R.A., Foy T.M., Aruffo A., Ledbetter J.A., and Noelle R.J. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261 (1993) 1328-1330
21. van Mierlo G.J., Boonman Z.F., Dumortier H.M., et al. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol 173 (2004) 6753-6759
22. Foy T.M., Page D.M., Waldschmidt T.J., et al. An essential role for gp39, the ligand for CD40, in thymic selection. J Exp Med 182 (1995) 1377-1388
23. Mapara M.Y., Kim Y.M., Wang S.P., Bronson R., Sachs D.H., and Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 100 (2002) 1903-1909
24. Mapara M.Y., Kim Y.M., Marx J., and Sykes M. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism. Transplantation 76 (2003) 297-305
25. Nakamura K., Inaba M., Sugiura K., et al. Enhancement of allogeneic hematopoietic stem cell engraftment and prevention of GVHD by intra-bone marrow bone marrow transplantation plus donor lymphocyte infusion. Stem Cells 22 (2004) 125-134
26. Suzuki Y., Adachi Y., Minamino K., et al. A new strategy for treatment of malignant tumor: intra-bone marrow-bone marrow transplantation plus CD4- donor lymphocyte infusion. Stem Cells 23 (2005) 365-370
27. Kolb H.J., Schmid C., Barrett A.J., and Schendel D.J. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103 (2004) 767-776
28. Eggert A.A., Schreurs M.W., Boerman O.C., et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 59 (1999) 3340-3345
29. Cui Y., Kelleher E., Straley E., et al. Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells. Nat Med 9 (2003) 952-958